Molecular testing in the diagnosis and management of hepatitis C virus infection

Archives of Pathology and Laboratory Medicine

Volumn 126, Issue 3, 2002, Pages 285-290

  Podzorski, Raymond P ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; NUCLEIC ACID AMPLIFICATION; POSTTRANSFUSION HEPATITIS; VIRUS LOAD;

ALGORITHMS; ANTIVIRAL AGENTS; BRANCHED DNA SIGNAL AMPLIFICATION ASSAY; GENETIC TECHNIQUES; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; VIRAL LOAD;

EID: 0036189360     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Hepatitis C: Natural history of a unique infection
2. Hepatitis C: Progress and problems
3. Hepatitis C
4. Prognostic factors determining the outcome of treatment in chronic hepatitis C
5. Genotype and viral load as prognostic indicators in the treatment of hepatitis C
6. Hepatitis C virus
7. National Institutes of Health Consensus Development conference statement: Management of hepatitis C
8. Randomized trial of interferon α2b plus ribavirin for 48 weeks for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
9. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
10. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
11. Detection of hepatitis C virus by a combined reverse transcription-polymerase chain reaction assay
12. Comparison of plasma virus loads among individuals infected with hepatitis C virus (HCV) genotypes 1, 2, and 3 by Quantiplex HCV RNA assay versions 1 and 2, Roche Monitor assay, and an in-house limiting dilution method
13. Diagnostic tests for hepatitis C
14. Assessment of viral loads in patients with chronic hepatitis C with Amplicor HCV Monitor version 1.0, COBAS HCV Monitor version 2.0, and Quantiplex HCV RNA version 2.0 assays
15. Comparative evaluation of hepatitis C virus RNA quantitation by branched DNA, NASBA, and Monitor assays
16. Collaborative study to assess the suitability of an HCV RNA reference sample for detection of an HCV RNA in plasma pools by PCR
17. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA
18. A proposed system for the nomenclature of hepatitis C viral genotypes
19. Molecular cloning and heterogeneity of the human hepatitis C virus (HCV) genome
20. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region
21. Analysis of a new hepatitis C virus type and its phylogenetic relationship to existing variants
22. Applications of six hepatitis C virus genotyping systems to sera from chronic hepatitis C patients in the United States
23. Hepatitis C genotyping by means of 5′-UR/core line probe assays and molecular analysis of untypeable samples
24. Distribution of hepatitis C genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States
25. Hepatitis C virus genotypes in the United States: Epidemiology, pathogenicity, and response to interferon therapy
26. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay
27. Relationship between hepatitis C genotype and severity of recurrent hepatitis C after liver transplantation
28. Sequence analysis of the 5′ untranslated region in isolates of at least four genotypes of hepatitis C virus in the Netherlands
29. Identification of hepatitis C virus genotypes among hospitalized patients in British Columbia, Canada
30. Genotyping of hepatitis C virus in South Africa
31. Rapid genotyping of hepatitis C virus
32. Survey of type 6 group variants of hepatitis C virus in Southeast Asia by using a core-based genotyping assay
33. Development of a simple restriction fragment length polymorphism (RFLP) based assay for HCV genotyping and comparative analysis with genotyping and serotyping tests
34. Determination of hepatitis C virus genotypes in the United States by cleavase fragment length polymorphism analysis
35. Algorithmic approach to high-throughput molecular screening for alpha interferon-resistant genotypes in hepatitis C patients
36. Plasma collected from heparinized blood is not suitable for HCV-RNA detection by conventional RT-PCR
37. Prospective comparison of whole-blood- and plasma-based hepatitis C virus RNA detection systems: Improved detection using whole blood as the source of viral RNA
38. Use of whole blood specimens for routine clinical quantitation of hepatitis C viral RNA does not increase assay sensitivity
39. Stability of hepatitis C virus RNA during specimen handling and storage prior to NASBA amplification
40. Hepatitis C virus stability: The issue!
41. Quantitation of hepatitis C virus genome molecules in plasma samples
42. Impact of specimen handling and storage on detection of hepatitis C virus RNA
43. Storage conditions of blood samples and primer selection affect yield of cDNA polymerase chain reaction products of hepatitis C virus
44. The stability of serum hepatitis C viral RNA in various handling and storage conditions
45. Impact of various handling and storage conditions on quantitative detection of hepatitis C virus
46. Stability of hepatitis C virus RNA in serum from samples collected in a closed-tube system for serum separation and transport, as measured by a quantitative competitive PCR assay
47. Effects of handling and storage of blood on the stability of hepatitis C virus RNA: Implications for NAT testing in transfusion medicine